Month: August 2016

Bedfont® Scientific, based in Harrietsham, Kent, launches their new ToxCO® breath carbon monoxide monitor which instantly diagnoses CO poisoning

Bedfont® Scientific has specialised in the design and manufacture of exhaled breath and gas monitoring instruments since 1976. With an unprecedented network of distributors, Bedfont’s products can be found in over 70 countries worldwide.

At the Emergency Services Show (ESS) 2016, Bedfont can be found at stand P94, introducing the new and improved ToxCO® carbon monoxide (CO) breath monitor. Here you will be able to see, test and provide your feedback for the chance to win a ToxCO® of your own; there will be three chances to win a ToxCO® and goody bags for all participants.

Bedfont Scientific’s ToxCO® monitor instantly diagnoses CO poisoning by analysing a breath sample from the patient to determine the level of CO in their blood. The ToxCO® monitor is a non-invasive tool, which provides instant results, unlike more traditional methods of testing for CO poisoning, like blood testing. This, in turn, saves valuable time when diagnosing a patient and reduces unnecessary hospital admissions.

The ToxCO® also comes with a face mask option for unconscious patients or young children, and an ambient air mode designed for emergency services, fire services and first responders to safeguard them by warning when there are high levels of CO in the atmosphere.

Available for pre-order now, the ToxCO® is quick, easy to use and non-invasive, making it the ideal tool for all emergency services; allowing you to continue saving lives, one breath at a time.

The NObreath® FeNO monitor from Bedfont Scientific could be the solution GP’s and patients are looking for to help asthma.

Figures released from the 2014 National Records of Scotland show that 122 people died from an asthma attack the previous year. This is an increase of 50 more deaths compared to 2013, two-thirds of which could have been prevented with better basic care, according to Asthma UK. Bedfont Scientific, who manufacture the NObreath® Fractional exhaled Nitric Oxide (FeNO) device, recommended by NICE , has been working with GP’s to implement the draft NICE asthma guidance which recommends FeNO testing in asthma management as part of a pilot hoping to improve basic asthma care and save future lives.

With this latest development in asthma figures sparking increasing concerns, especially following statistics released earlier this year from Asthma UK which found that over 120,000 asthma sufferers in the UK are at risk from wrongly prescribed medication and NICE’s findings that 30% of people with asthma are suspected to have been misdiagnosed, Bedfont Scientific are campaigning vigorously to raise awareness of FeNO measuring and it’s benefits.

Jason Smith, General Manager at Bedfont Scientific Ltd, explains,

“Nitric Oxide is naturally produced by the lungs to combat airway inflammation, therefore FeNO levels are higher in people with asthma and, by measuring these levels during diagnosis and management of the disease, it can improve basic asthma care. Using FeNO measurements to evaluate airway inflammation in asthma represent a significant advance in respiratory medicine, but this had been an expensive test to deliver in everyday practice, until now with the NObreath®.”

“Breath analysis with the NObreath® FeNO monitor is quick, simple and non-invasive, providing a better procedure for both the GP and the patient. By using the NObreath® FeNO monitor in basic asthma care, the GP will be able to not only determine the type of asthma (allergic or non-allergic) allowing the correct medication to be prescribed but also differentiate between asthma and other respiratory diseases such as COPD and ACOS through a process of elimination. Furthermore, the NObreath® shows patient adherence to prescription medicine allowing GP’s to adjust and prescribe the level of medication as necessary.”